Betulinic acid

Research use only, not for human use.

A naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial, and anti-inflammatory properties.

A naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial, and anti-inflammatory properties; shows to be a catalytic inhibitor of Topo II with IC50 values ranging from 0.38 to 58 uM; induces cell death through induction of apoptosis and inhibition of autophagic flux in microglia BV-2 cells.Chemotherapeutic Agents Suspended(In Vitro):Betulinic acid is a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and prevents topoisomerase I-DNA interaction. Betulinic acid (10, 20, 40, 80, and 160 μM) significantly suppresses MDA-MB-231 cell viability in a time- and dose-dependent manner after treatment for 24 or 48 h. Betulinic acid (20, 40 μM) causes decrease in Bcl-2 expression of MDA-MB-231 cells. Betulinic acid also induces morphological changes of MDA-MB-231 cells at 20 μM, and leads to ultrastructure changes of MDA-MB-231 cells at 40 μM. Betulinic acid shows anti-HIV activities, with an EC50 of 1.4 μM in acutely infected H9 lymphocytes.(In Vivo):Betulinic acid (10 and 30 mg/kg, p.o.) significantly abrogates colon shortening, and reduces malondialdehyde (MDA) and lipid hydroperoxide levels in dextran sulfate sodium (DSS)-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) restores superoxide dismutase (SOD), catalase activity and glutathione (GSH) content to control levels in DSS-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) also inhibits the DSS-induced increase in inflammatory markers. Betulinic acid (3, 10, 30 mg/kg, p.o.) suppresses acetic acid-induced writhing responses and mustard oil (MO)-induced visceral nociception in mice.

Betulinic acid is a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and prevents topoisomerase I-DNA interaction. Betulinic acid (10, 20, 40, 80, and 160 μM) significantly suppresses MDA-MB-231 cell viability in a time- and dose-dependent manner after treatment for 24 or 48 h. Betulinic acid (20, 40 μM) causes decrease in Bcl-2 expression of MDA-MB-231 cells. Betulinic acid also induces morphological changes of MDA-MB-231 cells at 20 μM, and leads to ultrastructure changes of MDA-MB-231 cells at 40 μM. Betulinic acid shows anti-HIV activities, with an EC50 of 1.4 μM in acutely infected H9 lymphocytes.

Betulinic acid (10 and 30 mg/kg, p.o.) significantly abrogates colon shortening, and reduces malondialdehyde (MDA) and lipid hydroperoxide levels in dextran sulfate sodium (DSS)-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) restores superoxide dismutase (SOD), catalase activity and glutathione (GSH) content to control levels in DSS-induced colitis in mice. Betulinic acid (30 mg/kg, p.o.) also inhibits the DSS-induced increase in inflammatory markers. Betulinic acid (3, 10, 30 mg/kg, p.o.) suppresses acetic acid-induced writhing responses and mustard oil (MO)-induced visceral nociception in mice.

Lupatic acid | Betulic acid

Cell Cycle/DNA Damage

Topoisomerase

AminopeptidaseN|EukaryotictopoisomeraseI|HIV-1

Cancer

Chemotherapeutic

472-15-1

456.7003

C30H48O3

>98% (HPLC)

10 mM in DMSO

O=C([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@@]3([H])CC[C@]4([H])[C@@]5(C)CC[C@H](O)C(C)(C)[C@]5([H])CC[C@@]4(C)[C@]3(C)CC1)O

Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3β)-

(-20℃)

With Ice Pack

≥ 2 years